Abstract
We report 3 patients with coronavirus disease who had a decline in respiratory status during their hospital course that responded well to intravenous steroids and interleukin-6 receptor antagonist therapy. These patients later showed development of persistent hypoxia with increased levels of d-dimer levels and were given a diagnosis of pulmonary embolisms.
Keywords:
COVID-19; SARS-CoV-2; coronavirus disease; d-dimer; deep vein thrombosis; hypercoagulability; prophylaxis; pulmonary embolism; respiratory infections; sequelae; severe acute respiratory syndrome coronavirus 2; thromboembolic; viruses.
MeSH terms
-
Acute Disease
-
Aged
-
Antibodies, Monoclonal, Humanized / therapeutic use
-
Anticoagulants / therapeutic use
-
Betacoronavirus / drug effects
-
Betacoronavirus / pathogenicity*
-
Betacoronavirus / physiology
-
Biomarkers / blood
-
COVID-19
-
COVID-19 Testing
-
Clinical Laboratory Techniques / methods
-
Coronavirus Infections / complications*
-
Coronavirus Infections / diagnosis
-
Coronavirus Infections / drug therapy
-
Coronavirus Infections / virology
-
Cytokine Release Syndrome / complications*
-
Cytokine Release Syndrome / diagnosis
-
Cytokine Release Syndrome / drug therapy
-
Cytokine Release Syndrome / virology
-
Enoxaparin / therapeutic use
-
Female
-
Fibrin Fibrinogen Degradation Products / metabolism*
-
Humans
-
Hypoxia / complications*
-
Hypoxia / diagnosis
-
Hypoxia / drug therapy
-
Hypoxia / virology
-
Male
-
Methylprednisolone Hemisuccinate / therapeutic use
-
Middle Aged
-
Pandemics
-
Pneumonia, Viral / complications*
-
Pneumonia, Viral / diagnosis
-
Pneumonia, Viral / drug therapy
-
Pneumonia, Viral / virology
-
Pulmonary Embolism / complications*
-
Pulmonary Embolism / diagnosis
-
Pulmonary Embolism / drug therapy
-
Pulmonary Embolism / virology
-
Rivaroxaban / therapeutic use
-
SARS-CoV-2
-
Tomography, X-Ray Computed
-
Treatment Outcome
Substances
-
Antibodies, Monoclonal, Humanized
-
Anticoagulants
-
Biomarkers
-
Enoxaparin
-
Fibrin Fibrinogen Degradation Products
-
fibrin fragment D
-
Methylprednisolone Hemisuccinate
-
Rivaroxaban
-
tocilizumab